Cargando…

The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis

A bulky, solitary hepatocellular carcinoma (HCC) with nonmajor branch portal vein tumor thrombosis (PVTT) was staged as T2 in the tumor-node-metastasis (TNM) system. We aimed to evaluate the prognosis of this group of patients. A total of 2643 patients with HCC in a medical center were consecutively...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Tyng-Yuan, Huang, Ching-I., Yeh, Ming-Lun, Lin, Zu-Yau, Chen, Shinn-Cherng, Chuang, Wan-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455711/
https://www.ncbi.nlm.nih.gov/pubmed/30921239
http://dx.doi.org/10.1097/MD.0000000000015066
_version_ 1783409680671834112
author Jang, Tyng-Yuan
Huang, Ching-I.
Yeh, Ming-Lun
Lin, Zu-Yau
Chen, Shinn-Cherng
Chuang, Wan-Long
author_facet Jang, Tyng-Yuan
Huang, Ching-I.
Yeh, Ming-Lun
Lin, Zu-Yau
Chen, Shinn-Cherng
Chuang, Wan-Long
author_sort Jang, Tyng-Yuan
collection PubMed
description A bulky, solitary hepatocellular carcinoma (HCC) with nonmajor branch portal vein tumor thrombosis (PVTT) was staged as T2 in the tumor-node-metastasis (TNM) system. We aimed to evaluate the prognosis of this group of patients. A total of 2643 patients with HCC in a medical center were consecutively enrolled. The stage of HCC was determined according to the 7th edition of American Joint Committee on Cancer staging system. Patients who were diagnosed as having solitary HCC larger than 5 cm with nonmajor portal vein thrombosis (VP1-VP2) and no lymphadenopathy or metastasis were included.Bulky HCC with nonmajor branch PVTT and without metastasis and lymphadenopathy was identified in 0.15% (4 out of 2643 patients) of the patients with HCC. Child–Pugh scores of the patients were A to B. Tumor sizes all were larger than 5 cm (mean: 6.8 ± 1.0 cm). All patients had nonmajor branch of PVTT. Three patients initially received trans-arterial chemoembolization (TACE) therapy, and 1 patient refused treatment because of old age. The response to TACE was poor: 2 patients rapidly progressed to main portal vein thrombosis, and their tumors enlarged within a half year. Only 1 patient's disease remained stable but progressed gradually 2 years later. The median survival time was 16.5 months. The 1- year, 2-year, and 3-year survival rate was 100%, 50%, and 0%, respectively. Solitary HCC > 5 cm with PVTT of a nonmajor branch gave dismal prognoses and required aggressive treatment such as hepatic resection or combination therapy. In our opinion, it should be staged as T3 rather than a T2 in the TNM staging system.
format Online
Article
Text
id pubmed-6455711
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64557112019-05-29 The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis Jang, Tyng-Yuan Huang, Ching-I. Yeh, Ming-Lun Lin, Zu-Yau Chen, Shinn-Cherng Chuang, Wan-Long Medicine (Baltimore) Research Article A bulky, solitary hepatocellular carcinoma (HCC) with nonmajor branch portal vein tumor thrombosis (PVTT) was staged as T2 in the tumor-node-metastasis (TNM) system. We aimed to evaluate the prognosis of this group of patients. A total of 2643 patients with HCC in a medical center were consecutively enrolled. The stage of HCC was determined according to the 7th edition of American Joint Committee on Cancer staging system. Patients who were diagnosed as having solitary HCC larger than 5 cm with nonmajor portal vein thrombosis (VP1-VP2) and no lymphadenopathy or metastasis were included.Bulky HCC with nonmajor branch PVTT and without metastasis and lymphadenopathy was identified in 0.15% (4 out of 2643 patients) of the patients with HCC. Child–Pugh scores of the patients were A to B. Tumor sizes all were larger than 5 cm (mean: 6.8 ± 1.0 cm). All patients had nonmajor branch of PVTT. Three patients initially received trans-arterial chemoembolization (TACE) therapy, and 1 patient refused treatment because of old age. The response to TACE was poor: 2 patients rapidly progressed to main portal vein thrombosis, and their tumors enlarged within a half year. Only 1 patient's disease remained stable but progressed gradually 2 years later. The median survival time was 16.5 months. The 1- year, 2-year, and 3-year survival rate was 100%, 50%, and 0%, respectively. Solitary HCC > 5 cm with PVTT of a nonmajor branch gave dismal prognoses and required aggressive treatment such as hepatic resection or combination therapy. In our opinion, it should be staged as T3 rather than a T2 in the TNM staging system. Wolters Kluwer Health 2019-03-15 /pmc/articles/PMC6455711/ /pubmed/30921239 http://dx.doi.org/10.1097/MD.0000000000015066 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Jang, Tyng-Yuan
Huang, Ching-I.
Yeh, Ming-Lun
Lin, Zu-Yau
Chen, Shinn-Cherng
Chuang, Wan-Long
The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
title The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
title_full The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
title_fullStr The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
title_full_unstemmed The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
title_short The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
title_sort prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455711/
https://www.ncbi.nlm.nih.gov/pubmed/30921239
http://dx.doi.org/10.1097/MD.0000000000015066
work_keys_str_mv AT jangtyngyuan theprognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT huangchingi theprognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT yehminglun theprognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT linzuyau theprognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT chenshinncherng theprognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT chuangwanlong theprognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT jangtyngyuan prognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT huangchingi prognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT yehminglun prognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT linzuyau prognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT chenshinncherng prognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis
AT chuangwanlong prognosisofbulkyhepatocellularcarcinomawithnonmajorbranchportalveintumorthrombosis